01. Lienhardt C, Nahid P, Rich ML, Bansbach C, Kendall EA, Churchyard G, González-Angulo L, D'Ambrosio L, Migliori GB, Raviglione M. Target regimen profiles for treatment of tuberculosis: a WHO document. European Respiratory Journal. 2017 Jan 1;49(1).
02.Bourgeois-Nicolaos N, Piriou O, Butel MJ, Doucet-Populaire F. Le linézolide: activité antibactérienne, intérêts cliniques et résistance [Linezolid: antibacterial activity, clinical efficacy and resistance]. Ann Biol Clin (Paris). 2006 Nov-Dec;64(6):549-64. French. PMID: 17162258
03.Karuppannasamy, D., Raghuram, A., & Sundar, D. (2014). Linezolid-induced optic neuropathy. Indian journal of ophthalmology, 62(4), 497–500. https://doi.org/10.4103/0301-4738.118451
04.Narita M, Tsuji BT, Yu VL. Linezolid‐associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2007 Aug;27(8):189-97.
05.Stalker, D. J., & Jung luth, G. L. (2003). Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clinical pharmacokinetics, 42(13), 1129–1140. https://doi.org/10.2165/00003088-200342130-00004
06. Chang, K. C., Leung, C. C., & Daley, C. L. (2013). Linezolid for multidrug-resistant tuberculosis - authors' reply. The Lancet. Infectious diseases, 13(1), 16–17. https://doi.org/10.1016/S1473-3099(12)70272-4
07. Agyeman AA, Ofori-Asenso R. Efficacy and safety profile of linezolid in multi drug-resistant and extensively drug-resistant tuberculosis: a systematic review and meta-analysis. Ann Clin Microbial Antimicrob. 2016;15:41.
08. Anger HA, Dworkin F et al. Linezolid use for treatment of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis, New York City, 2000–06.
09. Shah, R. K., & Lamichhane, S. (2017). Linezolid induced optic neuropathy, a serious yet reversible adverse effect: a case report. European Journal of Medical Case Reports, 1, 114-121.
10. Birmingham, M. C., Rayner, C. R., Meagher, A. K., Flavin, S. M., Batts, D. H., & Schentag, J. J. (2003). Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clinical Infectious Diseases, 36(2), 159-168.
11. De Vriese AS, Coster RV, Smet J, Seneca S, Lovering A, Van Haute LL, Vanopdenbosch LJ, Martin JJ, Groote CC, Vandecasteele S, Boelaert JR. Linezolid-induced inhibition of mitochondrial protein synthesis. Clin Infect Dis. 2006 Apr 15;42(8):1111-7. doi: 10.1086/501356. Epub 2006 Mar 13. PMID: 16575728.
12. Javaheri M, Khurana RN, O’hearn TM, Lai MM, Sadun AA. Linezolid-induced optic neuropathy: a mitochondrial disorder? British journal of ophthalmology. 2007 Jan 1;91(1):111-5.
13. Libershteyn Y. (2016). Ethambutol/Linezolid Toxic Optic Neuropathy. Optometry and vision science: official publication of the American Academy of Optometry, 93(2), 211–217. https://doi.org/10.1097/OPX.0000000000000783